REMEGEN (09995) shares surged 8.40% in intraday trading, riding the wave of a broader rally in Hong Kong's biotech sector. The stock's impressive gain is part of a sector-wide uptrend, with several other biotech companies also posting significant increases.

REMEGEN, a leading biopharmaceutical company focusing on the discovery, development, and commercialization of innovative and differentiated biologic drugs, has been attracting investor attention amidst the sector rally. The company's strong performance today aligns with gains seen in other major biotech players in the Hong Kong market, including 3SBIO, which jumped 11%, and SKB BIO, which rose 7%.

While specific catalysts for today's biotech sector rally were not immediately clear, the widespread gains suggest a positive sentiment towards the industry. Factors such as advancements in drug development, favorable regulatory news, or increased interest in healthcare investments could be driving this uptick. Investors appear to be showing renewed confidence in the biotech sector, with REMEGEN benefiting from this broader market movement.